Effect of Niacin in the Lipoprotein (a) Concentration
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Objectives.
- To evaluate the absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg
day of Niacin/Laropiprant in subjects with normal Lp(a) (< 30 mg/dL), high Lp(a) (30-60
mg/dL) and very high Lp(a) (> 60 mg/dL).
- To evaluate the absolute and relative Lp(a) lowering effect of 1g/20 mg and 2 g/40 mg
day of Niacin/Laropiprant depending on the number of kringle IV-2 repeated copies on the
apo(a) gene. 2.1.1 Hypotheses.
- The Lp(a) lowering effect of niacin is dependent of the pre-treatment Lp(a)
concentration, with higher absolute and relative reduction in Lp(a) in subjects with
hyperlipoproteinemia(a).
- Lp(a) size, throughout modifying hepatic synthesis of apo(a), is a major factor related
to the lowering effect variability of niacin in human.